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Two related questions led to the present experiments. What proportion of 
cells in lymphoblastoid lines transformed by Epstein-Barr virus (EBV) 1 con- 
tain sufficient viral genetic information to code for infectious viral particles and, 
by inference, contain the entire EB viral genome? Is the recently described en- 
hanced production of infectious EBV by simian lymphoblastoid cell lines due to 
differences in all cells or to a subpopulation of productive cells (1)? Both ques- 
tions were  approached by deriving single  cell  clones of human and monkey 
lymphoblastoid lines known to be producers of infectious virus detectable by 
the transformation assay. 
All  daughter  clones of human lymphoblastoid cell  lines express  EB  viral 
capsid antigens, provided that the parent line also contains these antigens (2-4). 
Therefore at least sufficient viral genetic information to code for capsid antigens 
is present in all cells, even though these antigens are demonstrable in less than 
10 % of human cells at any given time. Furthermore, clones of nonproducer lines 
exhibit  EBV  "early"  antigens  after  treatment  with  5P-bromodeoxyuridine 
(BUdR)  or  5-iodo-2'-deoxyuridine (IUdR)  (5).  Clones obtained in  previous 
studies have not been examined for infectious virus; consequently, the propor- 
tion of cells containing the necessary information to code for infectious virions 
is not known for any lymphoblastoid line. This question is difficult to study with 
EBV-transformed human lines, which, if productive, release minute quantities 
of virus. In fact, many human lymphoblastoid lines produce neither viral capsid 
antigens nor infectious virus even though they contain DNA which is comple- 
mentary to EB viral DNA (6, 7). In contrast, EBV-converted lymphoblastoid 
lines derived from blood leukocytes of new world primates release 100-1,000 
times more infectious virus than comparable human cells (1). Accordingly, the 
simian lines provide the means to determine, by cloning, the proportion of cells 
capable of producing mature virions. 
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Furthermore,  cloning studies  should allow a  choice between several possible 
hypotheses  to  account  for  enhanced  EB  virus  production  by  simian  as  con- 
trasted with human cells. First, simian and human lines might differ in the pro- 
portion of producer and nonproducer cells, with more producer cells being pres- 
ent in the simian lines. Second, only a  few cells in both human  and nonhuman 
lines might possess the information to release infectious virus, but more virus is 
released by this subpopulation of simian cells. Third, human lines might contain 
a  subpopulation  of cells which are inhibitory to formation of infectious virus by 
potentially productive cells. Fourth, all cells in both human and nonhuman lines 
might potentially be producers,  but the yield of virus from each activated  cell 
would be greater for simian than human  cells. Our results strongly support  the 
last alternative. 
Materials and Methods 
Cell Lines and Clones.--The human line (883L) was derived spontaneously from peripheral 
blood leukocytes of a patient with mononucleosis; the nonhuman primate lines were established 
from blood leukocytes of a squirrel monkey (line B84-15) and a cotton-top marmoset (line B93- 
8) after exposure to the Hawley strain of EB virus in the form of a filtered extract of line 883L 
(8). The culture medium for maintenance of cell lines and for cloning experiments was RPMI 
1640 with 10% fetal bovine serum, penicillin (50 U/ml), streptomycin (50 #g/ml), and ampho- 
tericin B  (1 #g/ml). 
To obtain clones logarithmic phase cells were resuspended at a concentration of 105/mi in 
complete medium. To eliminate the contribution of extracellular virus or virus adsorbed on 
the surface of cells 10% human serum with an EBV neutralizing antibody titer of ~  1 : 128 (9) 
was added. This serum (SW) was obtained from a patient 6 mo after infectious mononucleosis. 
The cell-serum mixture was held at 37°C in a water bath for 1 h and then further diluted to 
500-1,000 cells/nil. Clones were initiated by placing microdrops with single cells onto feeder 
layer of human placental cells (2). The same placental cell strain which is free of detectable 
EBV antigens was used for all experiments. Once growth of a clone was evident, subcultures 
thereafter were made in the absence of feeder ceils. Clones were maintained by weekly replace- 
ment of one-half the volume of cell suspension  with fresh medium. 
Assay/or EBV Antigens in Clones.--Viral capsid antigens were measured by the indirect 
immunofluorescence technique (10). EBV complement-fixing (CF) antigens were detected by 
the standard microtiter CF test, or by the recently described anticomplement immunofluores- 
cence test (11). Clones were examined for viral capsid and early antigens after treatment with 
5'-bromodeoxyuridine (5, 12-14).  Reference human sera with and without EBV antibody were 
used to measure all antigens. SW was the antibody-positive serum, and LH, from a healthy 
adult, was the antibody-negative serum. The human serum pool with high titer antibody to 
early antigen was a gift from W. Henle (15). 
Preparation of Clones  for Determination of Amount of Infectious EBV Released.=-The cell 
concentration of each clone was adjusted to 3  X  105/ml in fresh medium. The clones were in- 
cubated at 35°C for 1 wk; they reached a maximum density of 1.0-1.5  )<  106 cells/ml. Cells 
were sedimented at 500 g for 10 rain, the pellets were discarded, and the supernatant fluids were 
rapidly frozen and thawed three times and passed through a 0.8 #m Millipore filter. In one 
experiment cell-associated infectious virus in clones of the human line was determined in an 
extract  prepared  from  10 s  cells/ml. Cells were resuspended  in  fresh  medium,  frozen  and 
thawed, and filtered. 
Transformation Assay for Infectious EB V Released by the Clones.--The content of infectious 
EBV in the filtered fuids was assayed by transformation of primary umbilical cord leukocytes. 
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umbilical cord was placed in a tube with 0.2 ml of heparin (200 U). Red blood ceils were sedi- 
mented by addition of sufficient 3% (wt/vol) dextran (tool wt 280,000)  to bring the final con- 
centration to 1%. The supernatant obtained after 45 mill gravity sedimentation at room tem- 
perature was centrifuged at 500 g for 10 min, and the resultant cell pellet was washed three 
times by centrifugation in Puck's saline A.  Cells were reconstituted at  106/ml in medium 
RPMI  1640 with 20% fetal calf serum and  antibiotics. Gas phase was  5%  CO2/air.  After 
overnight incubation at 35°C,  the cell concentration was readjusted to 106/ml and 0.8 ml of 
cell suspension was dispensed to individual 150 X  16 mm tubes. An end-point dilution assay 
was employed; four replicate cukures were inoculated with 0.2 ml of each 10-fold virus dilution. 
Each assay was examined at 2 to 3-day intervals and held for 60 days. End points, expressed as 
50% transforming doses (TDs0) per 0.2 ml, were calculated by the Reed Muench formula (16). 
Transformation was marked by the appearance of large cell clumps,  acid production, and 
rapid increase in the number of cells. These signs first appeared approximately 21 days after 
addition of  virus. In  each transformation assay there were  four  replicate cultures of cord 
leukocytes unexposed to EBV; these always failed to transform. To control for possible varia- 
tions in different lots of cord leukocytes, a titration of a stock of EBV was performed in each 
test. Two reference virus stocks were prepared from frozen and thawed, filtered supernatant 
fluids of transformed marmoset leukocytes (line B95-8). 
Preparation of Virus  for Electron Microscopy.--From  each clone supernatant fluids collected 
1 wk after subculture were examined for viral particles. 60 ml of spent medium was centrifuged 
at 2000 rpm for 10 min in an International PR-2 centrifuge. The supernatant fluid was cen- 
trifuged at 28,000 rpm in a no. 30 rotor (Spinco Div., Beckman Instruments, Inc., Palo Alto, 
Calif.) for 2 h in a Beckman L-250 centrifuge. Each of the resulting pellets was reconstituted in 
1 ml of buffer (pH 7.4) composed of 1 M NaC1-0.1  M Tris-HCl-10 mM EDTA. 3 ml of recon- 
stituted pelleted material was placed on a discontinuous gradient of 4 ml 50% and 4 ml 10% 
potassium tartrate in the same buffer. After further centrifugation in an SW 41 rotor for 2 h 
at 25,000 rpm, the opalescent interface was collected by aspiration with a capillary pipette and 
reconstituted in 1 ml of buffer. The material examined by electron microscopy represented a 
60-fold concentration of the original tissue culture fluid.  Samples were placed on parlodion 
carbon-coated grids, stained with 2% phosphotungstic acid (pH 6.0), and examined in a Phil- 
ips EM-200. 
RESULTS 
Reproducibility  of the Assay for Infectious  EB V.--The  range of variability of 
the transformation assay performed on different batches of primary cord leuko- 
cytes was determined since the content of infectious virus released by all clones 
was not measured simultaneously.  Table I  lists 18 experiments, each with um- 
bilical cord leukocytes from a  different infant. The  two virus stocks used were 
prepared  from  supernatant  fluids  of  line  B95-8,  EBV-transformed  marmoset 
leukocytes. In 14 consecutive titrations, started from 4  to 141 days after prepa- 
ration  of  stock  A,  the median  transformation  titer  was  3.7  log10  TDs0/0.2  ml 
(range  3.0-4.5  log10 TD~0/0.2  ml).  There was  thus no major change in titer of 
EBV with 4  mo storage at -- 70C. Nearly identical results were obtained in four 
consecutive titrations of stock B  which was prepared after the cell line had been 
carried 4  additional too. The median value for the time to reach the end point 
was 36 days. 
Ej~cacy of Neutralizing  Antibody  Used to Obtain Clones of Producer Lines.- 
Clones were derived in the presence of antiserum to assure that  the results ob- GEORGE MILLER AND  MURIEL LIPMAN 
TABLE I 
Repeated Titrations of Two Stock Preparations of EB Virus on 
Different Lots of Human  Umbilical Cord Leukocytes 
1401 
Human umbilical  Time  Time to  Infectivity titer 
cord leukocyte  Virus stock  after virus  reach transformation  (LOgl0 
preparation  stock  prepared  end point  TD50/0,2 ml) 
days  days 
1  A*  4  42  4.3 
2  A  16  51  4.5 
3  A  30  47  3.8 
4  A  39  58  3.2 
5  A  43  49  3.5 
6  A  46  61  3.3 
7  A  78  28  3.5 
8  A  91  45  4.0 
9  A  92  43  4.5 
10  A  92  34  4.3 
11  A  128  41  3.2 
12  A  135  39  3.0 
13  A  137  38  3.5 
14  A  141  34  4.0 
Median stock A  36  3.7 
15  B*  0  31  3.8 
16  B  41  25  3.7 
17  B  42  32  4.0 
18  B  47  27  3.7 
Median stock B  31  3.8 
* Stock A was prepared on 4/10/72;  stock B  on 8/11/72;  both were stored at --70°C. 
Source of virus was line B95-8, transformed marmoset leukocytes. 
tained reflected the presence of the viral genome within the cell, rather  than 
viral particles adsorbed to the cell surface. Two  types of experiments demon- 
strated that all extracellular virus had been neutralized in the cloning suspen- 
sion. First, in each cloning experiment, after the suspension of l0  S cells/ml had 
been used for selecting microdrops with single cells, the suspension was frozen 
and thawed and the extract was tested for transforming ability. In all instances, 
there was no residual transforming activity. Second, reconstruction experiments 
determined the capacity of the antiserum employed to neutralize cell-associated 
and extracellular virus (Table II). A  suspension of 105 cells/ml of lines B84-15 
and B95-8 was incubated at 37°C for 1 h  in the presence of a  1:10 dilution of 
human  serum  containing EBV  antibody or human  serum  which  lacked EBV 
antibody. After incubation 10-fold dilutions to los and 103 cells/ml were made. 
Each cell concentration was then frozen and thawed three times and the suspen- 
sion  centrifuged  at  1,000  rpm  for  10  rain.  The  supernatants  were  tested for 
residual infectivity by transformation in four replicate cultures. The results indi- 1402  INFECTIOUS  VIRUS  YIELD  TRANSFORMED  BY  EBV 
cared that the antiserum neutralized all cell-associated infectivity in line B84-15. 
In line B95-8 there was some residual infectivity in an extract of 105 cells/ml but 
none in the extract which had contained 1@ cells/ml. Since suspensions contain- 
ing  103  cells/ml were used for cloning, it was  concluded that  all extracellular 
infectious virus was neutralized at the time of cloning by the EBV antiserum 
present in the medium. 
Cloning  E~ciency,  Derivation  of Clones,  and  Presence of EB  Viral  Capsid 
Antigens.--Preliminary  experiments demonstrated  that  the  plating  efficiency 
of the three lines from different primate species was less than 0.1%  in the ab- 
sence  of  a  feeder layer,  but  increased  to  16-24%  in  the  presence  of human 
placental feeder cells (Table III). Individual clones were  examined  for viral 
capsid antigen  (VCA)  by immunofluorescence  as soon as sufficient cells were 
available to do the test (usually 2-4 mo after cloning) and at intervals there- 
after.  16  of  17  clones demonstrated VCA on  the initial test;  the single clone 
without capsid antigen originated from EBV-transformed squirrel monkey cells. 
This clone has remained free of detectable VCA in the 15 mo since its derivation; 
TABLE II 
EBV Neutralizing Capacity of Human Serum Used in Cloning of 
EB V-Tranfformed Primate Cells 
No. cells/nil  used to 
prepare extract 
Line B84-15 (squirrel  monkey)  Line B95-8 (marmoset) 
Antlbody-positlve  Antibody-ncgatlve Antibody-positive Antibody-negative 
human serum  human serum  human serum  human serum 
105  0/4*  4/4  1/4  4/4 
104  0/4  4/4  0/4  4/4 
103  0/4  4/4  0/4  0/4 
* Number of cultures of human cord leukocytes demonstrating transformation per number 
inoculated with 0.2 ml of cell extract. 
TABLE III 
Cloning Efficiency and EB Viral Capsid Antiget~s in Single Cell Clones of a 
Human and Two Nonhuman Primate Lymphoblastoid Cell Lines 
No. clones  No. clones 
Method of  Cloning  with capsid  releasing 
Line  Source  transformation  Efficiency antigen  per  trans-  forming  no. tested  virus 
883 L  Mononucleosis  Spontaneous  6/25*  24%  6/6  5 
patient 
B84-15  Normal squirrel  EBV from 883L  6/32  19%  5/6  5 
monkey 
B95-8  Normal marmoset  EBV from 883L  6/38:~  16%  5/5:~  5 
* Number of clones per number of single cells plated. 
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however, it contained EBV complement-fixing antigens detectable both by the 
standard CF test and the anticomplement immunofluorescence test. Thus, in 
confirmation of previously published results with human cells, all simian clones 
contain the EBV genome. 
Serial determinations of  the  content of  viral capsid  antigen in each  clone 
showed a downward drift in the fraction of cells with VCA over the observation 
period of 12-26 mo (Table IV) ; in 14 of the 17 clones the highest proportion of 
cells with antigen was seen on the first examination. The fall in content of viral 
capsid antigen was most apparent in the human clones and least so in the mar- 
moset clones. The median level of VCA in the human clones after initiation was 
TABLE IV 
Serial Determination of Content of Viral Capsid Antigen in Clones of 
EB V-Transformed Human,  Squirrel Monkey,  and 
Marmoset Cells 
2  mo*  5  mo  7  mo  9  mo  12 mo  20 mo  26 mo 
Human line 883 L 
Clone 34  9.65  0.9  0.1  <0.1  0.7  3.2  0.5 
35  3.3  1.5  0.5  0.6  1.5  2.8  1.4 
42  3.5  0.4  0.2  <0.1  0.5  0.6  <0.1 
44  3.4  1.0  0.6  0.4  0.8  <0.I  <0.1 
50  1.8  0.9  1.5  0.4  1.1  0.8  <0.1 
52  2.2  0.3  <0.1  <0.1  <0.1  nil  nil 
4 mo  8 mo  15 mo 
Squirrel monkey line B84-15 
Clone  9  4.0  0.9  0.8 
13  6.2  2.3  1.7 
15  nil  nil  nil 
21  1.8  0.5  1.2 
30  5.2  1.9  1.1 
32  1.0  0.8  0.4 
3 mo  6 mo  12 mo 
Cotton-top marmoset line B95-8 
Clone 18  17.0  12.0  6.2 
20  12.7  10.0  5.8 
21  22.2  23.0  4.0 
22  14.4  7.3  5.9 
29  8.0  10.0  7.9 
* Months after seeding clones. 
Percent cells with viral capsid antigen. 500-1,000 cells counted after indirect immuno- 
fluorescence test  using  SW  (convalescent IM)  serum  and LH  (EBV-antibody  negative) 
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23%  of the median value at  the first examination; the comparable value for 
VCA in the marmoset clones was 40 % of the initial level. One clone of human 
origin completely lost evidence of nucleocapsid production. 
Biologically Active Virus Produced by Clones.--15 of the 17 primary clones re- 
leased infectious EBV.  Those derived from the human line, 883L, have been 
examined  at  three  different times using  cell  extracts 9  mo after cloning and 
supernatant fluids  12  and  20  mo after cloning.  Five of the six human  clones 
released infectious EBV on either two or three of the examinations (Table V), 
while the sixth clone, in which viral capsid antigen was at a very low level or not 
present, failed to release infectious virus on any examination. Five of the six 
clones of EBV-transformed squirrel monkey cells also released EBV; the sixth 
was negative for viral capsid antigen and also failed to release virus on repeated 
TABLE V 
Tests for Infectious Virus in Clones of Human Line gg3L 
Titer* of material tested for transformation at indicated time after cloning 
9 mo  12 mo  20 mo 
Clone 34  0.0,  1.5  1.5 
35  0.5  1.5  1.7 
42  <0.0  nil§  0.3 
44  0.3  0.5  nil 
50  nil  1.5  0.0 
52  nil  nil  nil 
Parent  1.3  1.3  <0.0 
* LOgl0 50% transforming doses per 0.2 ml as tested on human umbilical cord leukocytes. 
* 0.0, <  0.0  =  2 of 4 or 1 of 4 cultures transformed after inoculation of undiluted virus. 
§ No transformation. 
tests.  All  five clones of transformed marmoset leukocytes released infectious 
virus. 
Titers of infectious virus released by sister clones were similar and paralleled 
the amount of EBV released by the parent line  (Table VI). To illustrate,  the 
titers  of virus released by the human,  squirrel  monkey,  and  marmoset lines 
were, respectively, 101'3, 103.~, and 104.0 TDs0/0.2 ml; the median titers of virus 
released by their respective daughter clones were 101.5, 103 .0, 104"3 TDs0/0.2 ml. 
The amount of virus released estimated from electron micrographic examina- 
tion  correlated  well  with  measurements made  by  the  transformation  assay. 
Viral particles were not seen in 60-fold concentrates prepared from clones of the 
human line, with a  low level infectivity; herpes virus particles were found in 
fluid concentrated from two of the squirrel monkey clones and from all of the 
marmoset ones. Approximately 66 % of the virus particles from squirrel monkey 
and 84 % of the particles from marmoset clones were enveloped (Fig. 1). These GEORGE  MILLER  AND  MURIEL  LIPMAN  1405 
results indicate that differences among clones are not due to the production of 
biologically inactive viral particles by clones which yield low levels of infectious 
EBV. 
From the data presented in Table VI, the amount of infectious virus released 
per activated cell can be estimated for the producer clones3 In these calculations 
TABLE  VI 
Infectious Viru3 and Viral Particles in Supernatant Fluids from Individual Clones* 
Viral particles 
Viral  Calc. 
Line  Clone  capsid  Infectivity§  Yieldll  No. grid  De-  En- 
antigens  squares  examined  tected veloped Naked 
883L¶  (human)  Parent  0.017  100  0.006  5  -- 
34  0.032  158  0.005  5  -- 
35  0.028  251  0.009  5  -- 
42  0.006  10  0.002  5  -- 
44  < 0.001  nil  nil  5  -- 
50  0.008  5  0.001  5  -- 
52  nil  nil  nil  5  -- 
B84-15¶  (squir-  Parent  0.017  2,506  0.147  5  +  6 
rel  monkey)  9  0.040  998  0.025  5  +  15 
13  0.062  9,980  0.161  5  +  5 
15  nil  nil  nil  5  -- 
21  0.018  5,000  0.278  5  -- 
30  0.052  5,000  0.096  5  -- 
32  0.010  100  0.010  5  -- 
B95-8¶  (mar-  Parent  0.103  50,000  0.485  3  +  44 
moset)  18  0.170  158,150  0.930  1  +  82 
20  0.127  99,800  0.786  3  +  43 
21  0.222  99,800  0.450  1  +  ND** 
22  0.144  50,000  0.347  7  +  25 






* An aliquot of the same supernatant fluid was tested for infectious virus and,  after 60X 
concentration by eentrifugation, was examined for viral particles. 
Fraction of cells with immunofluorescence based on counts of 1,000 cells. 
§ Infectivity  =  no. 50% transforming units/ml. 
No. 50% transforming units/ml 
]] Yield of EBV  = 
Fraction cells with VCA X  106 cells/ml. 
¶ The data are based on examination of 883L  clones at 20 mo, B84-15  clones at 4 mo, 
and B95-8 clones at 3 mo after derivation. 
** ND  =  not done; although this preparation had many enveloped and naked virions a 
differential count was not made. 
2 In this paragraph the statements are based on the following median values for human, 
squirrel monkey, and marmoset clones, respectively: viral capsid antigens: 0.018, 0.040,  and 
0.144; infectious virus per milliliter: 84, 5,000, and 99,800; yield of infectious virus per cell with 
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Fro. 1.  A group of seven EB virus particles partially purified from supernatant fluids of a 
clone of transformed marmoset cells. Each nucleocapsid displaying typical herpes virus mor- 
phology is enclosed in an envelope that is partially ruptured. Bar represents 100 nm. 
the cell number at the time of virus harvest is considered to be 106/ml for all 
clones and the number of activated cells per milliliter is obtained by applying 
the percent cells with viral capsid antigen  to 106/ml.  Squirrel  monkey clones 
contained approximately twice the number of cells with viral capsid antigen as 
human clones; however, the squirrel monkey clones yielded on the average 27 
times more infectious virus. Marmoset clones contained 8 times more cells with 
VCA than human  clones and,  furthermore,  these cells yielded  approximately 
200 times more infectious virus than human clones. Thus, enhanced virus pro- 
duction by simian clones resulted from both an increased proportion of activated 
cells and an increased yield of virus from each activated cell. For each species the 
median yield of infectious cell-free virus by productive daughter clones closely 
paralleled the yield of virus by the parent although  there was some variation 
among individual clones of each species. Human transformants all yielded less 
than 10 infectious units per 1,000 VCA-positive cells; the median for productive 
squirrel monkey clones was 96 infectious U/1,000 virogenic cells (range 10-278 
TDs0/1,000 VCA-positive cells)  while for marmoset clones it was 786 infectious 
U/l,000 VCA-positive cells (range 347-1,977 TD~0/1,000). 
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far we have not been able to rescue biologically active virus from two nonpro- 
ducer clones (human clone 52 and squirrel monkey clone 15) by treatment with 
BUdR or by X  irradiation followed by co-cultivation with primary marmoset 
leukocytes  (Table vii).  BUdR  treatment  caused  the  appearance  of antigens 
detectable by immunofluorescence in 1-2 %  of cells in the nonproducer squirrel 
monkey clone but not in the human clone. Neither  infectious virus nor viral 
particles detectable by electron microscopy were found in fluids of nonproducer 
clones after BUdR treatment. The content of infectious virus from the BUdR- 
treated productive marmoset clone was reduced to 4 % of the value without drug 
treatment. 
TABLE VII 
Attempt to Induce Nonproducer Clones to Release Infectious 
Virus by Treatment with 5'-Bromodeoxyuridlne 
Line  Clone 
Control  BUdR-treated* 
Antigens detected by  Antigens detected by 
•  (1)  "  (1)  immunofluorescence  immunofluorescenee  In-  In- 
fectious  "early" +  fectious 
Viral  "early" +  virus~  Viral  virus:~  viral  viral 
capsid ( 2 )  capsid ( 3 )  capsid ( ~  )  capsid ( 3 ) 
883 L human  Clone 52  nil  nil  nil  nil  nil  nil 
B84-15 squirrel  Clone 15  nil  nil  nil  1.0  2.2  nil 
monkey 
B95-8 marmoset  Clone 18  15.0  28.6  3.7  18.4  25.0  2.3 
(1) A serum with only antibodies against viral capsid antigen  (SW), (2) and a serum pool 
which contained  antibodies against  early antigens  (3), and viral capsid antigens were used. 
Number is the percent ceils with antigens.  1,000 cells enumerated  per slide. 
* Logarithmic  phase  cultures  treated  with  5'-bromodeoxyuridine  (25 #g/ml)  or RPMI 
medium as a control for 40 h. Cells were washed three times and replaced in fresh medium. 
They were tested for IF antigens and infectious virus 1 wk after removal of the drug. 
~Logt0 50% transforming doses per 0.2 ml. 
Exposure of the two nonproducer clones to 8,000 R  did not cause the appear- 
ance of antigens detectable by immunofluorescence 3 or 7 days after irradiation. 
These lethally X-irradiated cells were unable to cause transformation of primary 
marmoset leukocytes. As a positive control lethally X-irradiated producer cells 
of marmoset clone 22 caused transformation of primary marmoset leukocytes. 
With some human lymphoblastoid lines similar methods have proved capable 
of  demonstrating  small  amounts  of biologically  active  virus  (12,  17-19).  If 
rescue experiments had been successful with the nonproducer clones, they would 
have indicated  that  even  those  clones contain  information for elaboration  of 
biologically active virus. 
Attempt to Superinfect Nonproducer Clones.--Superinfection  of the two non- 
producer clones was attempted in order to investigate the possibility of a helper- 1408  INFECTIOUS  VIRUS  YIELD  TRANSFORMED  BY  EBV 
virus phenomenon. EB virus was concentrated and partially purified from line 
B95-8 by the procedure used to prepare virions for electron microscopy. Each 
nonproducer clone at a cell concentration of 107/ml was resuspended in 1 ml of 
virus containing 10  ~.° TD~0/ml. After 4 h  the inoculum was removed, and the 
cells were washed and resuspended in fresh medium at 5 X  105 cells/ml. Cells 
harvested 3 and 7 days after superinfection demonstrated neither viral capsid 
antigen nor early antigens, and supernatant fluids from cultures 7 days after 
superinfection did not contain infectious EBV. 
DISCUSSION 
Differences in the Yield of Infectious EBV by Clones of Human, Squirrel Mon- 
key, and Marmoset Lymphoblastoid Cell Lines.---Our results indicate that daugh- 
ter clones, with the exception of the two nonproducer clones encountered, re- 
semble their parent in the amount of infectious virus released. Thus differences 
between human and simian lines are not primarily due to effects of particular 
subpopulations of cells, but to differences which reside in most, though perhaps 
not all, individual transformed cells. Since differences between the lines can be 
generalized to differences between single clones, and since all three lines were 
transformed by the same EBV strain, it seems reasonable to conclude that there 
are cellular mechanisms which regulate the expression of the viral genome in 
EBV-transformed cells. The results presented indicate that there are quantita- 
tive, if not qualitative, differences in these mechanisms among primate species. 
The data do not allow a choice between the two alternatives which are that the 
human cells lack facilitating factor(s) or that they possess inhibitory factor(s). 
Both types of processes, namely "cytoplasmic essential replication factors" and 
"repressors," have been described in comparative studies of cell lysis and cell 
transformation after infection with SV~0 (20, 21). In fact, the clonal lines of SV40- 
transformed human embryo lung cells,  described by Kit and Dubbs, behaved 
similarly to clonal lines of EBV-transformed human lymphoid cells. Nearly all 
clones contained the SV40 genetic information needed for production of infec- 
tious virus, but less than one in one hundred thousand SV40-transformed human 
cells actually formed infectious centers. 
Data obtained in earlier work in our laboratory also provide evidence that 
differences in the production of infectious EBV by transformants of different 
species is due to cell variation and not to genetic variation in the virus (1). One 
could argue that human  line 883L was  transformed by a  low-yielding virus 
variant, that squirrel monkey line B84-15 was transformed by an intermediate 
virus, and that line 1395-8 was transformed by a highly productive variant. This 
argument is excluded by previous findings that transformants from several indi- 
viduals of each species all behave similarly: low yields from human cells, high 
from marmoset cells,  and  intermediate from squirrel  monkey cells.  Another 
possibility is that passage in marmoset cells permanently modifies the virus to a 
high yielding state. This possibility is unlikely, for marmoset-grown virus is non- GEORGE  MILLER  AND  MURIEL  LZPMAN  1409 
productive in human cells,  and EB virus obtained from throat washings  and 
which has never been in cell culture leads to productive transformation in mar- 
moset cells and nonproductive transformation of human cells (22). A third hy- 
pothesis, which seems implausible but which is difficult to exclude experimen- 
tally,  is  that  there  is  a  very high  mutation  and  back-mutation  rate  in  the 
property of the virus responsible for high and low yield and that human cells are 
selectively transformed  by  low-yielding virus  variants  and  simian  cells  are 
transformed by high yielding virus. 
Since 15 of 17 clones tested produced infectious EBV, it may tentatively be 
concluded that the majority of cells in the three lines studied contain the com- 
plete EB viral genome. However, it has not yet been rigorously demonstrated 
which viral components are needed for lymphocyte transformation. In experi- 
ments in which EBV has been partially purified, transforming activity is asso- 
ciated with the viral particle per se (23-24). It has not yet been conclusively 
shown whether naked nucleocapsids as well as enveloped particles possess trans- 
forming activity. There is no information yet about the proportion of the viral 
genome which is necessary for transformation. With these reservations it none- 
theless seems reasonable to suggest on the basis  of our data that  enveloped 
virions are the usual initiators of transformation. We have previously shown 
that  treatment  with  ether  abolishes  transformation  by  EBV.  The  electron 
microscopic survey for viral particles performed in conjunction with assays for 
infectivity demonstrated that enveloped particles were most numerous in the 
marmoset clones which also yielded the highest titers of infectious virus. By 
using a  semi-quantitative estimate of viral particle counts  (25), we calculate 
that the particle infectivity ratio of EB virions produced in marmoset clones is 
approximately 40-300 to 1. 
In the present experiments it was possible to verify that all extracellular in- 
fectious virus was absent from cell suspensions used for cloning. This result sup- 
ports previous hypotheses that the EBV genome in an intracellular location is 
associated with all cells. Our studies with clones do not shed light on the molecu- 
lar  basis  of the  relationships between  the  viral  and  cellular genomes,  but  a 
recent report by Nonoyama and  Pagano  suggests  that  the  EBV  genome is 
present on cell chromosomes, though it may not be covalently linked to cellular 
DNA (26). On the basis of reassociation kinetics between EBV DNA and cell 
DNA from the  nonproductive Raji line,  these same  investigators have  con- 
cluded that the Raji cells contain a complete copy of the EBV genome (27). 
Significance of the Nonproducer Clones.--Two clones did not release infectious 
EBV on repeated examinations; nonetheless, these clones contain EBV genetic 
material. The nonproductive human clone produced capsid antigen for several 
months, and the nonproductive squirrel monkey clone spontaneously produced 
EBV antigens detectable by immunofluorescence after treatment with BUdR. 
Since the yield of infectious virus from human clones is low, the nonyielding 
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if concentrated fluids were examined. Failure to detect virus from the squirrel 
monkey clone is more meaningful since 10~-°-10  3'° infections U/0.2 ml were ex- 
pected by comparison with other clones in that series. 
The nonproducer clones may result from either viral or cellular mechanisms. 
They may have been derived after transformation by defective virions or pos- 
sibly they may result from excision of part of the viral genome from some cells. 
As a possible explanation the absence of a helper virus seems less likely since we 
could not convert the nonproducer clones to yield virus by superinfection. We 
favor the hypothesis that nonproducer clones result from restrictions imposed 
by the cell. Cells may differ in the restriction of viral replication not only be- 
tween species, but also within a  species. A  nonproducer clone may originate 
from a  different cell type than its  producer sisters,  for example,  a  different 
lymphocyte subtype. Age of the donor may also be a factor since we have dem- 
onstrated  that  transformed human umbilical  cord leukocytes rarely produce 
viral capsid antigens, whereas these antigens  are frequently present in trans- 
formed lenkocytes from adults  (1). The observation that  in cloned lines the 
proportion of cells with viral capsid antigen decreases with time and that some 
producer clones become nonproducers is compatible either with the existence of 
selection processes which favor nonproducer cells,  or with progressive loss of 
viral information. 
The availability of producer and nonproducer sister clones provides starting 
material for study of the mechanisms of restriction of expression of the EBV 
genome. Among the questions for future study is whether nonproducer clones 
are also more restrictive for other viruses, either those of the herpes group or 
unrelated agents. 
SUMMARY 
Three lymphoblastoid cell lines, of human, squirrel monkey, and marmoset 
origin, all transformed by the same strain of Epstein-Barr virus (EBV), differed 
markedly in their content of infectious virus. Single cell clones were obtained 
from each line to learn whether these differences were dependent upon factors 
shared by all cells in each line or upon factors present only in a proportion of the 
total cell population. 
A total of 17 primary clones were examined: 6 human, 6 squirrel monkey, and 
5  marmoset.  Cloning  efficiency on human  placental  cell  feeder layers varied 
from 16 to 24%. EBV antiserum, present in the cloning suspension, was shown 
to neutralize all extracellular virus. 15 of the 17 clones released EBV as meas- 
ured by the transformation assay. Titers of infectious virus released by daughter 
clones paralleled titers of virus in the parent line. The median virus titers from 
human, squirrel monkey, and marmoset clones were respectively 101"5, 103.0, and 
104.3 50% transforming doses per 0.2 ml. The median yield of virus from clones 
of the  three species was,  respectively, 4,  96,  and  786  transforming units per 
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Two nonproducer clones (one human and one squirrel  monkey) did not re- 
lease infectious virus after treatment with 5'-bromodeoxyuridine, or with X  ray 
followed by co-cultivation with marmoset leukocytes. The nonproducer clones 
could not be superinfected by biologically active EBV. 
These results show that differences in production of infectious EBV among 
the lines  tested  are reflected  in the  majority of cells of these lines.  The data 
imply that the mechanism for regulation of the expression of the EBV genome 
is cellular rather than viral in origin. There are presumably genetic differences 
among primate species in this regulatory process. 
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